Encouraging patient adherence to medication is very important to managing the cost of multiple sclerosis (MS) therapies, said Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, director, outcomes research, WelldyneRx.
Encouraging patient adherence to medication is very important to managing the cost of multiple sclerosis (MS) therapies, said Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, director, outcomes research, WelldyneRx.
Transcript
MS therapies are very expensive—are there any strategies you recommend that can help manage these costs?
One of the most important strategies in order to manage MS patients is really to get the adherent on their therapy. As patients become adherent and stay on their medications, particularly those first-line agents, they’re less likely to have relapses and less likely to develop disability later on, as well as reduce the number of relapses. By staying on those first-line agents, which tend to be less expensive than second- or third-line agents, you end up actually decreasing overall prescription drug costs by having patients more adherent to their medication.
What do you recommend to get patients more adherent?
So, to get patients more adherent is actually a very multifactorial process. There’s not just one size fits all. So, it’s really going to have to be very patient specific. There’s different types of learners and different types of patients out there with different levels of health literacy, as well as different levels of understanding and acceptance of their disease state. So, it really takes a pharmacist to be able to use motivational interviewing skills to present the information and have the patient digest that information and understand it. It’s important to not overwhelm patients, because they’re already being overwhelmed with having this disease state and having all these things to know about their drug. So, it’s important to not just do one-time education and call it a day. It’s important to provide ongoing education in small digestible forms of information for patients to really be able to start accepting and understanding their disease state.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
April 17th 2024A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More